Evidence map›Paper›PMID 33342284›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2021

Post-treatment with glycyrrhizin can attenuate hepatic mitochondrial damage induced by acetaminophen in mice.

Xue-Liang Dang, Long-Fei Yang, Lei Shi, Long-Fei Li, Ping He, Jie Chen, Bei-Jie Zheng, Peng Yang, Ai-Dong Wen

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. miR-375 protects against acetaminophen-induced acute liver failure by orchestrating pharmacogene expression.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xue-Liang DangDepartment of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an 710032, China.
Long-Fei YangDepartments of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.
Lei ShiDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710038, China.
Long-Fei LiDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710038, China.
Ping HeRenji Hospital, Medical School of Shanghai Jiaotong University, Shanghai 200127, China.
Jie ChenRenji Hospital, Medical School of Shanghai Jiaotong University, Shanghai 200127, China.
Bei-Jie ZhengRenji Hospital, Medical School of Shanghai Jiaotong University, Shanghai 200127, China.
Peng YangDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710038, China.ORCID 0000-0002-0274-9627
Ai-Dong WenDepartment of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an 710032, China.
Xijing Hospital · CNRenji Hospital · CNAir Force Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overdose of acetaminophen (APAP) is responsible for the most cases of acute liver failure worldwide. Hepatic mitochondrial damage mediated by neuronal nitric oxide synthase- (nNOS) induced liver protein tyrosine nitration plays a critical role in the pathophysiology of APAP hepatotoxicity. It has been reported that pre-treatment or co-treatment with glycyrrhizin can protect against hepatotoxicity through prevention of hepatocellular apoptosis. However, the majority of APAP-induced acute liver failure cases are people intentionally taking the drug to commit suicide. Any preventive treatment is of little value in practice. In addition, the hepatocellular damage induced by APAP is considered to be oncotic necrosis rather than apoptosis. In the present study, our aim is to investigate if glycyrrhizin can be used therapeutically and the underlying mechanisms of APAP hepatotoxicity protection. Hepatic damage was induced by 300 mg/kg APAP in balb/c mice, followed with administration of 40, 80, or 160 mg/kg glycyrrhizin 90 min later. Mice were euthanized and harvested at 6 h post-APAP. Compared with model controls, glycyrrhizin post-treatment attenuated hepatic mitochondrial and hepatocellular damages, as indicated by decreased serum glutamate dehydrogenase, alanine aminotransferase, and aspartate aminotransferase activities as well as ameliorated mitochondrial swollen, distortion, and hepatocellular necrosis. Notably, 80 mg/kg glycyrrhizin inhibited hepatic nNOS activity and its mRNA and protein expression levels by 16.9, 14.9, and 28.3%, respectively. These results were consistent with the decreased liver nitric oxide content and liver protein tyrosine nitration indicated by 3-nitrotyrosine staining. Moreover, glycyrrhizin did not affect the APAP metabolic activation, and the survival rate of ALF mice was increased by glycyrrhizin. The present study indicates that post-treatment with glycyrrhizin can dose-dependently attenuate hepatic mitochondrial damage and inhibit the up-regulation of hepatic nNOS induced by APAP. Glycyrrhizin shows promise as drug for the treatment of APAP hepatotoxicity.

Indexed as

AcetaminophenAnimalsGlycyrrhizic AcidLiverMaleMiceMice, Inbred BALB CMitochondria, LiverNitric OxideNitric Oxide Synthase Type INitrosationTyrosineUp-RegulationAcetaminophenGlycyrrhizic AcidNitric OxideNitric Oxide Synthase Type ITyrosineacetaminophen hepatotoxicityGlycyrrhizinmitochondrial damageneuronal nitric oxide synthaseprotein adductstyrosine nitration

Identifiers

PMID33342284
PMCPMC8142107
OpenAlexW3116208509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.